{"article_title": "ASHP disappointed in 340B orphan drug court decision", "article_keywords": ["hrsa", "340b", "court", "drugs", "disappointed", "decision", "orphan", "drug", "program", "used", "rural", "ashp", "hospitals"], "article_url": "https://www.pharmacist.com/ashp-disappointed-340b-orphan-drug-court-decision", "article_text": "The American Society of Health-System Pharmacists (ASHP) on Friday said it is extremely disappointed in the recent court decision by the U.S District Court for the District of Columbia that will exclude all drugs with an \"orphan\" designation from the 340B Drug Pricing Program for rural and cancer hospitals. The court on October 14 struck down an interpretive rule by the Health Resources and Services Administration (HRSA) that allowed rural hospitals and other facilities newly eligible for 340B discounts to use the program to purchase orphan drugs when the product will not be used for the orphan indication. \"This ruling will limit access to critical medications for the sickest patients in our health care system,\" said Kasey Thompson, PharmD, ASHP Vice President of Policy, Planning, and Communications. \"ASHP has long maintained that the interpretation by HRSA of the orphan drug provisions of the Affordable Care Act was correct and that rural and cancer hospitals should be able to access orphan drugs under the 340B program when used for non-orphan indications.\"", "article_metadata": {"og": {"site_name": "American Pharmacists Association", "description": "The American Society of Health-System Pharmacists (ASHP) on Friday said it is extremely disappointed in the recent court decision by the U.S District Court for the District of Columbia that will e", "title": "ASHP disappointed in 340B orphan drug court decision", "url": "https://www.pharmacist.com/ashp-disappointed-340b-orphan-drug-court-decision", "image": "/sites/default/files/images/APhA-footer-logo.png", "updated_time": "2015-10-19T09:00:01-04:00", "type": "article"}, "article": {"published_time": "2015-10-19T09:00:01-04:00", "modified_time": "2015-10-19T09:00:01-04:00"}, "generator": "Drupal 7 (http://drupal.org)", "description": "The American Society of Health-System Pharmacists (ASHP) on Friday said it is extremely disappointed in the recent court decision by the U.S District Court for the District of Columbia that will e", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fdf995\"", "article_summary": "The American Society of Health-System Pharmacists (ASHP) on Friday said it is extremely disappointed in the recent court decision by the U.S District Court for the District of Columbia that will exclude all drugs with an \"orphan\" designation from the 340B Drug Pricing Program for rural and cancer hospitals.\n\"ASHP has long maintained that the interpretation by HRSA of the orphan drug provisions of the Affordable Care Act was correct and that rural and cancer hospitals should be able to access orphan drugs under the 340B program when used for non-orphan indications.\"\nThe court on October 14 struck down an interpretive rule by the Health Resources and Services Administration (HRSA) that allowed rural hospitals and other facilities newly eligible for 340B discounts to use the program to purchase orphan drugs when the product will not be used for the orphan indication.\n\"This ruling will limit access to critical medications for the sickest patients in our health care system,\" said Kasey Thompson, PharmD, ASHP Vice President of Policy, Planning, and Communications."}